File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Toward developing a once-a-month pill: a double-blind, randomized, controlled trial of the effect of three single doses of mifepristone given at midcycle on the pattern of menstrual bleeding

TitleToward developing a once-a-month pill: a double-blind, randomized, controlled trial of the effect of three single doses of mifepristone given at midcycle on the pattern of menstrual bleeding
Authors
KeywordsMifepristone
once-a-month pill
pattern of menstrual bleeding
Issue Date2006
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/fertnstert
Citation
Fertility And Sterility, 2006, v. 86 n. 4, p. 819-824 How to Cite?
AbstractObjective: To test the feasibility of timing the administration of mifepristone as a once-a-month contraceptive pill on the 12th day before the next menses, as calculated from the length of the previous menstrual cycles. Design: Double-blind, randomized, controlled trial. Setting: Five family planning centers across the world. Patient(s): Three hundred ninety-nine women attending family planning clinics. Intervention(s): Randomized to receive 10, 25, or 200 mg of mifepristone or a placebo. Main Outcome Measure(s): Lengthening or shortening of the normal menstrual cycle length following administration of the drug by at least 5 days. Result(s): The menstrual period came within 5 days of the predicted date in 88% of women receiving the placebo, 84% of women receiving 10 mg, 72% of women receiving 25 mg of mifepristone, and only 48% of women treated with 200 mg of mifepristone. Increasing the dose of mifepristone was associated with an increased chance of having a delayed period (P<.001). Only 45% of women were in the peri-ovulatory phase of the cycle according to LH and P measurements on the day of drug administration. Women treated before ovulation were more likely to have delayed menses with all three doses of mifepristone. Conclusion(s): Because of the disruption in cycle length, it appears unlikely that mifepristone administered once a month, at a calendar-based time, would provide a reliable method of contraception. © 2006 American Society for Reproductive Medicine.
Persistent Identifierhttp://hdl.handle.net/10722/87239
ISSN
2015 Impact Factor: 4.426
2015 SCImago Journal Rankings: 2.156
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNarvekar, Nen_HK
dc.contributor.authorGlasier, Aen_HK
dc.contributor.authorDada, Ken_HK
dc.contributor.authorVan Der Spuy, Zen_HK
dc.contributor.authorHo, PCen_HK
dc.contributor.authorCheng, Len_HK
dc.contributor.authorBaird, DTen_HK
dc.date.accessioned2010-09-06T09:27:07Z-
dc.date.available2010-09-06T09:27:07Z-
dc.date.issued2006en_HK
dc.identifier.citationFertility And Sterility, 2006, v. 86 n. 4, p. 819-824en_HK
dc.identifier.issn0015-0282en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87239-
dc.description.abstractObjective: To test the feasibility of timing the administration of mifepristone as a once-a-month contraceptive pill on the 12th day before the next menses, as calculated from the length of the previous menstrual cycles. Design: Double-blind, randomized, controlled trial. Setting: Five family planning centers across the world. Patient(s): Three hundred ninety-nine women attending family planning clinics. Intervention(s): Randomized to receive 10, 25, or 200 mg of mifepristone or a placebo. Main Outcome Measure(s): Lengthening or shortening of the normal menstrual cycle length following administration of the drug by at least 5 days. Result(s): The menstrual period came within 5 days of the predicted date in 88% of women receiving the placebo, 84% of women receiving 10 mg, 72% of women receiving 25 mg of mifepristone, and only 48% of women treated with 200 mg of mifepristone. Increasing the dose of mifepristone was associated with an increased chance of having a delayed period (P<.001). Only 45% of women were in the peri-ovulatory phase of the cycle according to LH and P measurements on the day of drug administration. Women treated before ovulation were more likely to have delayed menses with all three doses of mifepristone. Conclusion(s): Because of the disruption in cycle length, it appears unlikely that mifepristone administered once a month, at a calendar-based time, would provide a reliable method of contraception. © 2006 American Society for Reproductive Medicine.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/fertnsterten_HK
dc.relation.ispartofFertility and Sterilityen_HK
dc.rightsFertility and Sterility. Copyright © Elsevier Inc.en_HK
dc.subjectMifepristoneen_HK
dc.subjectonce-a-month pillen_HK
dc.subjectpattern of menstrual bleedingen_HK
dc.titleToward developing a once-a-month pill: a double-blind, randomized, controlled trial of the effect of three single doses of mifepristone given at midcycle on the pattern of menstrual bleedingen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0015-0282&volume=86&issue=4&spage=819&epage=824&date=2006&atitle=Toward+developing+a+once-a-month+pill:+a+double-blind,+randomized,+controlled+trial+of+the+effect+of+three+single+doses+of+mifepristone+given+at+midcycle+on+the+pattern+of+menstrual+bleedingen_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.fertnstert.2006.02.115en_HK
dc.identifier.pmid17027354-
dc.identifier.scopuseid_2-s2.0-33749253856en_HK
dc.identifier.hkuros127736en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33749253856&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume86en_HK
dc.identifier.issue4en_HK
dc.identifier.spage819en_HK
dc.identifier.epage824en_HK
dc.identifier.isiWOS:000241165400007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNarvekar, N=6506862459en_HK
dc.identifier.scopusauthoridGlasier, A=35370179000en_HK
dc.identifier.scopusauthoridDada, K=19638325400en_HK
dc.identifier.scopusauthoridVan Der Spuy, Z=35461457500en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK
dc.identifier.scopusauthoridCheng, L=34869443100en_HK
dc.identifier.scopusauthoridBaird, DT=35371609800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats